These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 17548728)

  • 1. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome.
    Ray KK; Morrow DA; Sabatine MS; Shui A; Rifai N; Cannon CP; Braunwald E
    Circulation; 2007 Jun; 115(24):3071-8. PubMed ID: 17548728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
    Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
    J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
    Ray KK; Cannon CP; McCabe CH; Cairns R; Tonkin AM; Sacks FM; Jackson G; Braunwald E;
    J Am Coll Cardiol; 2005 Oct; 46(8):1405-10. PubMed ID: 16226162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome.
    Nazer B; Ray KK; Sloan S; Scirica B; Morrow DA; Cannon CP; Braunwald E
    Eur Heart J; 2011 Jun; 32(11):1390-7. PubMed ID: 21345849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
    Ridker PM; Morrow DA; Rose LM; Rifai N; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2005 May; 45(10):1644-8. PubMed ID: 15893181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
    Murphy SA; Cannon CP; Wiviott SD; de Lemos JA; Blazing MA; McCabe CH; Califf RM; Braunwald E
    Am J Cardiol; 2007 Oct; 100(7):1047-51. PubMed ID: 17884359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22).
    Ray KK; Morrow DA; Shui A; Rifai N; Cannon CP
    Am J Cardiol; 2006 Oct; 98(7):861-5. PubMed ID: 16996863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein levels and outcomes after statin therapy.
    Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
    N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Sasiela WJ; Szarek M; Ganz P; Libby P;
    Circulation; 2004 Jul; 110(4):386-91. PubMed ID: 15262833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
    O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
    Rouleau J
    Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    Cannon CP; Braunwald E; McCabe CH; Rader DJ; Rouleau JL; Belder R; Joyal SV; Hill KA; Pfeffer MA; Skene AM;
    N Engl J Med; 2004 Apr; 350(15):1495-504. PubMed ID: 15007110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study).
    Khera AV; Qamar A; Murphy SA; Cannon CP; Sabatine MS; Rader DJ
    Am J Cardiol; 2015 Sep; 116(5):694-8. PubMed ID: 26119654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
    Khera AV; Wolfe ML; Cannon CP; Qin J; Rader DJ
    Am J Cardiol; 2010 Aug; 106(4):451-6. PubMed ID: 20691300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.
    Scirica BM; Morrow DA; Cannon CP; Ray KK; Sabatine MS; Jarolim P; Shui A; McCabe CH; Braunwald E;
    J Am Coll Cardiol; 2006 Jun; 47(11):2326-31. PubMed ID: 16750703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
    J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial.
    de Lemos JA; Morrow DA; Blazing MA; Jarolim P; Wiviott SD; Sabatine MS; Califf RM; Braunwald E
    J Am Coll Cardiol; 2007 Nov; 50(22):2117-24. PubMed ID: 18036447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris.
    Avanzas P; Arroyo-Espliguero R; Quiles J; Roy D; Kaski JC
    Eur Heart J; 2005 Mar; 26(5):457-63. PubMed ID: 15684278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.